The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a research note.
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Structure Therapeutics’ American depositary receipts gained more than 6% premarket on Monday after the company said its ...
Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death ...
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...
Structure's once-daily oral drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk's blockbuster weight-loss drug Wegovy and Eli Lilly's Zepbound. Leerink analysts said in a note ...